← Back to Clinical Trials
Recruiting NCT05463289

NCT05463289 ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05463289
Status Recruiting
Phase
Sponsor Johns Hopkins University
Condition Type 1 Diabetes
Study Type INTERVENTIONAL
Enrollment 500 participants
Start Date 2022-07-11
Primary Completion 2026-09-30

Eligibility & Interventions

Sex All sexes
Min Age 8 Years
Max Age 21 Years
Study Type INTERVENTIONAL
Interventions
Point of Care Autonomous AI diabetic retinopathy exam

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 500 participants in total. It began in 2022-07-11 with a primary completion date of 2026-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to determine if use of a nonmydriatic fundus camera using autonomous artificial intelligence software at the point of care increases the proportion of underserved youth with diabetes screened for diabetic retinopathy, and to determine the diagnostic accuracy of the autonomous AI system in detecting diabetic retinopathy from retinal images of youth with diabetes.

Eligibility Criteria

Inclusion Criteria: Meets American Diabetes Association (ADA) criteria for diabetic retinopathy screening: * Diagnosis of Type 1 diabetes for ≥3 years, and age 11 or in puberty * Diagnosis of Type 2 diabetes Enriched cohort: * Patients with Type 1 or Type 2 diabetes, * 8-21 years of age with known diabetic retinopathy (true positives). * No time limit on last diabetic eye exam. Exclusion Criteria: * Known diabetic eye exam in the last 12 months

Contact & Investigator

Central Contact

Risa M Wolf, MD

✉ RWolf@jhu.edu

📞 4109556463

Principal Investigator

Risa M Wolf, MD

PRINCIPAL INVESTIGATOR

Johns Hopkins University

Frequently Asked Questions

Who can join the NCT05463289 clinical trial?

This trial is open to participants of all sexes, aged 8 Years or older, up to 21 Years, studying Type 1 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05463289 currently recruiting?

Yes, NCT05463289 is actively recruiting participants. Contact the research team at RWolf@jhu.edu for enrollment information.

Where is the NCT05463289 trial being conducted?

This trial is being conducted at Baltimore, United States.

Who is sponsoring the NCT05463289 clinical trial?

NCT05463289 is sponsored by Johns Hopkins University. The principal investigator is Risa M Wolf, MD at Johns Hopkins University. The trial plans to enroll 500 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology